01—Abstract
Summary
Summary of the 10-Q filed May 1, 2026. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific Inc. reported strong revenue growth of 6% for the first quarter of 2026, reaching $11.0 billiona, driven by robust performance in the pharmaceutical and biotech sectors.
While overall revenue saw a healthy increase, the academic and government, and diagnostics and healthcare markets experienced declines. The company demonstrated significant strategic activity with the acquisition of Clario Holdings, Inc. for $9.099 billionb, expanding its clinical trial data solutions capabilities.
Conversely, Thermo Fisher also announced the divestiture of its microbiology business for approximately $1.075 billionc, expected to close in the second half of 2026. These strategic moves, alongside a substantial $3 billion in share repurchases and $0.16 billion in dividends paid, highlight the company's active capital allocation strategy.
02—Key points
Key Highlights
- Total revenues increased by 6% to $11.0 billion compared to the prior year's first quarter.
- The company completed a significant acquisition of Clario Holdings, Inc. for $9.099 billion to bolster its clinical trial data solutions.
- Thermo Fisher announced the planned divestiture of its microbiology business for approximately $1.075 billion, expected to close in late 2026.
- Share repurchases totaled $3.0 billion in the first quarter, demonstrating a commitment to returning capital to shareholders.
- Operating income grew by 9% to $1.9 billion, with an operating margin of 16.9%.
- Cash provided by operating activities increased significantly to $1.2 billion, and free cash flow more than doubled to $825 million.
- The company reported a substantial increase in goodwill on the balance sheet, largely driven by the Clario acquisition.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2026filed May 1, 2026Financial Statements
Q1 FY2026 against Q1 FY2025
| Line item | Q1 FY2026Q1 FY2025 | Change |
|---|---|---|
| Revenue | $11.01B$10.36B | +6.2% |
| R&D Expenses | $336.00M$342.00M | −1.8% |
| SG&A Expenses | $2.18B$2.08B | +5.0% |
| Operating Expenses | $9.14B$8.65B | +5.7% |
| Operating Income | $1.86B$1.72B | +8.6% |
| Net Income | $1.66B$1.51B | +9.6% |
| EPS (Basic) | $4.44$3.99 | +11.3% |
| EPS (Diluted) | $4.43$3.98 | +11.3% |
| Shares Outstanding (Basic) | 372.00M378.00M | −1.6% |
| Shares Outstanding (Diluted) | 373.00M379.00M | −1.6% |
05—Questions
Frequently Asked Questions
What were the key drivers of Thermo Fisher's revenue growth in the first quarter of 2026?
Revenue growth was primarily driven by strong performance in the pharmaceutical and biotech market, which benefited from strengthening underlying market conditions. The Laboratory Products and Biopharma Services segment and, to a lesser extent, the Life Sciences Solutions segment were key contributors to organic revenue growth.
How did the Clario acquisition impact the company's financial position?
The acquisition of Clario Holdings, Inc. significantly increased the company's total assets and goodwill. The purchase price was approximately $9.1 billion, funded through a combination of cash, debt settlement, and other considerations. This strategic move aims to expand the company's clinical research offerings.
What is the outlook for the company's debt levels?
Total debt increased to $43.2 billion from $39.4 billion at the end of the prior year. This increase is largely due to debt issuance to finance acquisitions, share repurchases, and general corporate purposes. The company maintains a revolving credit facility and has access to capital markets, with management believing its liquidity will be sufficient for at least the next 24 months.
How is the company managing its capital allocation?
Thermo Fisher Scientific is actively managing its capital through a combination of strategic acquisitions (like Clario), planned divestitures (microbiology business), significant share repurchases totaling $3.0 billion in the quarter, and dividend payments of $0.16 billion. The company continues to prioritize mergers and acquisitions, followed by share buybacks and dividends.
06—Continue